NEW YORK, Sept. 13, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Blaize Holdings, Inc. (NASDAQ: BZAI) between July 18, 2025 and April 28, 2026, both dates inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

So what: If you purchased Blaize securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Blaize class action, go to https://rosenlegal.com/cases/blaize-holdings-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Blaize announced transactions with entities wholly unequipped to conduct meaningful business in order to create an appearance of growth; (2) Blaize improperly recognized revenue; and (3) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Blaize class action, go to https://rosenlegal.com/cases/blaize-holdings-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY  10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected] 

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

NEW YORK, Sept. 13, 2026 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Microvast Holdings, Inc. (NASDAQ: MVST) between April 1, 2025 and March 16, 2026, inclusive (the "Class Period"), of the important September 21, 2026 lead plaintiff deadline.

So what: If you purchased Microvast securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Microvast class action, go to https://rosenlegal.com/cases/microvast-holdings-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 21, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) due to, inter alia, inventory management issues and delays in commercial vehicle rollouts by Microvast's customers, defendants had overstated Microvast's ability to reach its margin targets; (2) defendants overstated Microvast's ability to complete the Huzhou Phase 3.2 expansion by the end of 2025; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Microvast class action, go to https://rosenlegal.com/cases/microvast-holdings-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected]

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

The article explains key parts of a homeowners insurance policy that every first-time buyer should understand before filing a claim.

CAPE GIRARDEAU, Mo., Sept. 13, 2026 /PRNewswire/ -- What does homeowners insurance actually cover? A HelloNation article featuring insights from Insurance Agent Nick Hogan provides the answer by explaining the parts of a homeowners insurance policy that first-time buyers often overlook and why understanding them before moving in can help prevent costly surprises.

The article explains that many first-time homeowners focus on their purchase price, mortgage, and moving expenses while spending less time learning how their homeowners insurance works. Understanding a homeowners insurance policy before a covered loss occurs can help homeowners make informed decisions and feel more prepared if they ever need to file a claim.

According to the article, many people mistakenly believe homeowners insurance protects only the structure of a house. In reality, a homeowners insurance policy often includes several different types of protection that work together. Learning what each part covers allows homeowners to better understand how their policy responds in different situations.

The HelloNation article explains that one of the primary components of homeowners insurance is coverage for the home's structure. If a house is damaged by a covered event such as fire, hail, or wind, the policy may help pay for repairs or rebuilding. The article encourages homeowners to review their coverage periodically to make sure it continues to reflect the value of their home.

Another important feature discussed in the article is personal property coverage. Personal property coverage helps protect belongings such as furniture, clothing, electronics, kitchen appliances, and other possessions if they are damaged or stolen during a covered event. The article notes that many first-time homeowners underestimate the value of their belongings and recommends creating a home inventory to better understand whether their current protection is sufficient.

The article also highlights the importance of liability coverage. If someone is injured on a homeowner's property or the homeowner accidentally causes damage to another person's property, liability coverage may help pay certain covered costs. While these situations may not happen often, understanding how liability coverage works helps homeowners recognize the broader protection included within their policy.

Another topic covered in the article is additional living expenses coverage. If a home cannot be occupied because of a covered loss, additional living expenses coverage may help pay for temporary housing, meals, and other eligible living expenses while repairs are completed. The article explains that this coverage can ease financial stress during an already difficult situation.

The article also encourages homeowners to understand how their deductible affects both premiums and claim costs. A deductible represents the amount a policyholder pays before insurance begins covering a covered loss. Choosing a higher deductible may lower monthly premiums while increasing out-of-pocket expenses following a claim. Selecting a lower deductible generally has the opposite effect.

The article emphasizes the importance of reviewing coverage limits and understanding policy exclusions. Coverage limits establish the maximum amounts an insurance company may pay for covered losses, while policy exclusions identify situations that are not included under a standard homeowners insurance policy. Damage caused by floods or earthquakes, for example, may require separate insurance depending on where a homeowner lives.

The article concludes that homeowners insurance should be reviewed as life changes occur. Home improvements, new belongings, and changing household needs can all affect the amount and type of protection that makes sense. Regularly reviewing a homeowners insurance policy helps ensure coverage continues to align with both the home and the homeowner's financial goals.

What First-Time Homeowners Often Miss About Insurance features insights from Nick Hogan, Insurance Agent of Cape Girardeau, Missouri, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

SAN DIEGO, Sept. 13, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UWM Holdings Corporation (NYSE: UWMC) securities between March 9, 2026 and August 5, 2026, both dates inclusive (the "Class Period"), have until Tuesday, October 13, 2026 to seek appointment as lead plaintiff of the UWM class action lawsuit. Captioned Bond v. UWM Holdings Corporation, No. 26-cv-12862 (E.D. Mich.), the UWM class action lawsuit charges UWM and certain of UWM's top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the UWM class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-uwm-holdings-corporation-class-action-lawsuit-uwmc.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: UWM engages in the origination, sale, and servicing residential mortgage lending. According to the complaint, in December 2025, UWM and Two Harbors Investment Corp. signed an all-stock merger agreement valued at $1.3 billion to expand UWM's mortgage servicing rights. Allegedly, in March 2026, Two Harbors Investment Corp. terminated the UWM agreement due to a competing offer and agreed to pay UWM's termination fee.

The UWM class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) UWM had deviated from its traditional strategy of not hedging its mortgage servicing rights to take a major hedge position; (ii) UWM over-hedged itself in anticipation of the Two Harbors Investment Corp. transaction; (iii) UWM's purported efforts to balance its risk in fact created an excess hedging risk; and (iv) that, as a result of the foregoing, defendants' positive statements about UWM's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 5, 2026, after the market closed, UWM reported second quarter fiscal year 2026 financial results, allegedly including a nearly $603.2 million interest rate derivatives loss which contributed to a $451.9 million second quarter net loss, and that total equity fell 43.6% year over year, reflecting the net loss and derivative-related charges. Then, on August 6, 2026, UWM held an earnings call in connection with its second quarter 2026 financial results. According to the complaint, UWM's Chief Executive Officer, Mathew Ishbia, disclosed "[w]e were over-hedged, if you think of it that way, protecting against the Two Harbors transaction" and that "[w]e don't traditionally hedge our MSRs [Mortgage Servicing Rights]" but "when you're going through and acquiring a company like Two Harbors and a massive MSR book… it created a little more risk. So . . . we did put a hedge on to protect against that risk and then a lot of things happen[ed]…and then obviously, the Two Harbors transaction went away. And so a confluence of events that created a hedge loss." On this news, the price of UWM shares fell nearly 35%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired UWM securities during the Class Period to seek appointment as lead plaintiff in the UWM class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the UWM class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the UWM class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the UWM class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices. 

Contact:

Robbins Geller Rudman & Dowd LLP

Ken Dolitsky

Michael Albert

655 W. Broadway, Suite 1900, San Diego, CA 92101

800/851-7783

[email protected] 

SOURCE Robbins Geller Rudman & Dowd LLP

Share this article

NEW YORK, Sept. 13, 2026 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hyliion Holdings Corp. (NYSE American: HYLN) between May 12, 2026 and June 23, 2026, both dates inclusive (the "Class Period"), of the important October 27, 2026 lead plaintiff deadline.

So what: If you purchased Hyliion securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Hyliion class action, go to https://rosenlegal.com/cases/hyliion-holdings-corp/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or omitted material facts concerning the credibility of its announced commercial pipeline, notably, the basis for management's confidence in its VFG Holdings ("VFG") partnership and the extent of Hyliion's evaluation of VFG's operational capabilities, financial resources, and ability to perform before announcing the "new data center partnership" as a significant commercial opportunity. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hyliion class action, go to https://rosenlegal.com/cases/hyliion-holdings-corp/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY  10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected]

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

SAN DIEGO, Sept. 13, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until tomorrow, Monday, September 14, 2026 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron as well as certain of Regeneron's top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Regeneron class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-regeneron-pharmaceuticals-class-action-lawsuit-regn.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders worldwide.

The Regeneron class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information demonstrating that Regeneron's Phase III Fianlimab-Libtayo Study was well-poised for success, while minimizing risks to the study's odds of achieving its primary endpoint and its overall statistical validity arising from the prolonged event rate slowdown; (ii) Regeneron's preliminary statistical assumptions were fundamentally flawed; (iii) the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies; and (iv) the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.

On April 29, 2026, during Regeneron's first quarter earnings call, defendants allegedly disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, the price of Regeneron stock declined more than 6%, according to the complaint.

Then, after-market on May 15, 2026, Regeneron issued a press release allegedly announcing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, the price of Regeneron stock dropped nearly 10%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Regeneron common stock during the Class Period to seek appointment as lead plaintiff in the Regeneron class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Regeneron class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Regeneron class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Regeneron class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Contact:

Robbins Geller Rudman & Dowd LLP

Ken Dolitsky

Michael Albert

655 W. Broadway, Suite 1900, San Diego, CA 92101

800/851-7783

SOURCE Robbins Geller Rudman & Dowd LLP

Share this article

The Target-Exclusive Launch Pairs Bright Berry Flavor With GORGIE's Clean, Functional Formula

NEW YORK, Sept. 13, 2026 /PRNewswire/ -- GORGIE, the modern energy drink redefining the category with clean ingredients and no artificial sweeteners, announced today the launch of Berry Burst, a bold new flavor inspired by the juicy berry taste consumers know and love.

Berry Burst is juicy, craveable, and playful — a refreshing take on a classic favorite, reimagined for today's wellness-minded consumer.

Known for blending function with flavor, GORGIE created Berry Burst to deliver an energizing boost without sacrificing ingredient quality, taste, or aesthetic. Each can contains 150mg of green tea caffeine alongside functional ingredients including Biotin, B Vitamins, and L-Theanine. With zero grams of sugar, five calories, and no artificial sweeteners, Berry Burst delivers the functional energy GORGIE fans love.

Wrapped in the rich purple tones defining this fall season, the new flavor is designed to look just as good in your hand as it tastes in every sip.

"Berry is having a moment, and we wanted to give her the full GORGIE treatment," said Michelle Cordeiro Grant, Founder and CEO of GORGIE. "Berry Burst started with the idea that your drink can double as your best accessory. Purple is having its it-girl moment this fall, and this flavor feels bright, bold, polished, and a little unexpected. Whether you are running to a meeting, heading to a workout, getting ready for Fashion Week, or making late-night plans, Berry Burst was created to bring feel-good energy to every part of your day."

Inspired by the rich hues of fall and the idea that a drink can double as the perfect accessory, GORGIE took Berry Burst to the streets of New York City for its debut campaign. Styled alongside leather, fall jackets, and polished seasonal looks, Berry Burst felt perfectly at home bringing a little Fashion Week energy to the beverage aisle.

The launch arrives during a period of significant retail growth for GORGIE, which now has nearly 60,000 points of distribution in the marketplace and is on track to reach 100,000 in early 2027.

"Consumers are showing us that modern energy is not a niche. It is the next evolution of the category," added Cordeiro Grant. "They want ingredients they recognize, benefits that support their days, flavors they genuinely crave, and a can they are excited to carry. Berry Burst brings all of that together!"

Berry Burst will be available exclusively at Target locations nationwide beginning September 13th.

About GORGIE:

GORGIE is the fastest-growing modern energy brand in the United States, redefining the category with better-for-you ingredients, functional benefits, and a community-driven approach where energy meets wellness. Each can features 150mg of green tea caffeine alongside wellness-supporting ingredients including Biotin, B Vitamins, and L-Theanine, delivering smooth, sustained energy without the jitters or crash. GORGIE is vegan, gluten-free, and free from artificial sweeteners, including aspartame, sucralose, and erythritol.

Built on the mission to create a more elevated alternative within the energy space, GORGIE blends taste, function, beauty, and culture in a way that resonates with today's modern wellness consumer. Built community-first, GORGIE has evolved beyond a beverage brand into Club GORGIE, the brand's members-only app experience offering exclusive access to product drops, events, rewards, and insider experiences for its highly engaged community.

Founded by Michelle Cordeiro Grant in 2022, GORGIE officially launched its first line of sparkling energy drinks in January 2023. The company is backed by Notable Capital and Coefficient Capital, along with other strategic partners. GORGIE has quickly become one of the fastest-growing natural energy drink brands in the country. Retail sales are up 600% year over year, GORGIE is available in more than 15,000 stores I think this is doors, but if they are counted as the same thing, then this is okay nationwide, and it is the No. 1 independent energy drink brand at Targetyes. At a leading national natural retailer, GORGIE now holds nearly 20% of the energy category, almost tripling its share from approximately 7% one year ago. yes

GORGIE is available direct-to-consumer on GETGORGIE.COM and Amazon, as well as in thousands of retail locations nationwide. GORGIE is a community, a brand, and a platform on a mission to make wellness fun, with products that support energy for all-day, everyday life.

For more information, visit getgorgie.com and follow @getgorgie on Instagram and TikTok.

Media Contact

Amanda Bosco, [email protected]

SOURCE GORGIE

Share this article

Phase III MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for Small-Cell Lung Cancer

MRI surveillance without prophylactic cranial irradiation improved cognitive failure-free survival and substantially reduced serious treatment-related adverse events

SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- Results from the international phase III SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC). The findings support MRI surveillance alone as the standard of care for patients with SCLC, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

For decades, PCI has been used after initial therapy for SCLC because studies conducted before routine MRI demonstrated that it reduced brain metastases and improved overall survival. MAVERICK was designed to determine whether modern MRI surveillance could allow patients to avoid PCI—and its potential cognitive and other toxicities—without compromising survival.

The trial enrolled 304 patients with limited-stage or extensive-stage SCLC between January 2020 and December 2025. All participants had completed initial therapy and had no brain metastases on MRI before enrollment. Patients were randomly assigned to MRI surveillance alone or MRI surveillance plus PCI (25 Gy in 10 fractions). In both groups, brain MRIs were performed every three months during the first year and every six months during the second year, with cognitive testing conducted at the same intervals. The study's cognitive assessments included the Hopkins Verbal Learning Test-Revised, Controlled Oral Word Association and Trail Making Test.

At a median follow up of 22 months among living patients, MRI surveillance alone significantly improved cognitive failure-free survival, the trial's primary endpoint, reducing the risk of cognitive failure or death by 40% compared with MRI plus PCI (HR 0.60; 90% CI 0.46–0.78; p=0.001). The benefit was similar among patients with limited-stage and extensive-stage disease and regardless of whether patients received immunotherapy.

A preliminary overall survival analysis, conducted after 128 deaths, showed no apparent difference between the treatment strategies (HR for the MRI alone arm, 0.90; 90% CI 0.67–1.20). The final overall survival analysis is planned after 190 deaths. Brain metastasis-free survival also was not significantly different between the two groups (HR 1.25; 90% CI 0.95–1.66).

Serious treatment-related adverse events were less frequent with MRI surveillance alone. Grade 3–5 adverse events occurred in 0.8% of patients receiving MRI surveillance alone compared with 7.9% of those receiving MRI plus PCI (p=0.004). One grade 5 encephalopathy event occurred in the MRI plus PCI group.

"MRI surveillance alone was associated with improved cognitive failure-free survival compared to a strategy of MRI surveillance plus PCI. The benefit of MRI surveillance alone also appears to be consistent across patients with both limited-stage and extensive-stage small-cell lung cancer," said Chad Rusthoven, MD, of the University of Colorado School of Medicine and the study presenter. "These results support MRI surveillance alone as the standard of care for patients with SCLC."

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

Contact: Chris Martin, IASLC Media Relations, [email protected]

SOURCE International Association for the Study of Lung Cancer

Share this article

Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer

Anti-B7-H3 antibody-drug conjugate reduced the risk of death by 54% versus topotecan and improved

progression-free survival and response rates

SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Relapsed SCLC remains a highly aggressive disease with limited effective treatment options and poor outcomes following first-line immunotherapy and platinum-based chemotherapy. Topotecan has long been a standard second-line treatment, but its survival benefit remains modest. TAISHAN-302 evaluated Tam-Peli as a second-line treatment for patients whose SCLC had relapsed after first-line therapy.

The randomized, open-label study enrolled 451 patients, with 225 assigned to Tam-Peli and 226 to topotecan. Patients receiving Tam-Peli were treated with 2.0 mg/kg intravenously on day 1 of each three-week cycle, with a maximum dose of 200 mg. Treatment continued until disease progression or unacceptable toxicity. The study's primary endpoint was overall survival, with progression-free survival and objective response rate as key secondary endpoints.

As of May 20, 2026, after a median follow-up of 9.4 months, median overall survival was 13.3 months with Tam-Peli compared with 9.4 months with topotecan. Tam-Peli reduced the risk of death by 54% (HR 0.46; 95% CI 0.35–0.62; p0.0001). The survival benefit was consistent across prespecified subgroups, including patients with brain metastases, liver metastases and a chemotherapy-free interval of less than 90 days.

Tam-Peli also significantly improved progression-free survival. Median progression-free survival was 7.4 months with Tam-Peli versus 2.8 months with topotecan, representing a 71% reduction in the risk of disease progression or death (HR 0.29; 95% CI 0.23–0.37; p0.0001). The objective response rate was 59.1% with Tam-Peli compared with 9.7% with topotecan (p0.0001).

The safety profile of Tam-Peli was considered manageable and consistent with its known profile, with no new safety signals identified. Grade 3 or higher treatment-related adverse events occurred in 46.4% of patients receiving Tam-Peli compared with 74.7% receiving topotecan, and there were no treatment-related deaths in the Tam-Peli arm. Treatment-emergent interstitial lung disease or pneumonitis occurred in 4.9% of patients receiving Tam-Peli and 1.4% receiving topotecan; grade 3 events occurred in 0.9% of patients in each group, with no grade 4 or 5 events reported.

"TAISHAN-302 is among the first phase III studies of an antibody-drug conjugate to demonstrate statistically significant and clinically meaningful improvements in overall survival, progression-free survival and objective response rate compared with topotecan in relapsed small-cell lung cancer," said Professor Li Zhang of Sun Yat-sen University Cancer Center, Guangzhou, China. "Together with a generally favorable and manageable safety profile, these results support Tam-Peli as a potential new standard-of-care option for second-line SCLC and may reshape the treatment landscape for this challenging disease."

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

Contact: Chris Martin, IASLC Media Relations, [email protected]

SOURCE International Association for the Study of Lung Cancer

Share this article

Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer

B7-H3-directed antibody-drug conjugate reduced the risk of death by 54% compared with topotecan

and improved progression-free survival and response rates

SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy. The findings were presented today at the IASLC 2026 World Conference on Lung Cancer (WCLC).

ARTEMIS-008 (NCT06498479) is a multicenter, open-label, randomized Phase III study. A total of 461 patients in China were randomized 1:1 to receive Ris-Rez 8.0 mg/kg every three weeks or topotecan 1.2 mg/m² on days 1 through 5 every three weeks. More than 80% of patients had previously received PD-(L)1 inhibitors. The primary endpoint was overall survival, with progression-free survival, objective response rate, disease control rate and safety among the key secondary endpoints.

At the June 6, 2026 data cutoff, after a median follow-up of 12.2 months, median overall survival was 18.5 months with Ris-Rez compared with 10.3 months with topotecan. Ris-Rez reduced the risk of death by 54% (HR 0.46; 95% CI, 0.35–0.62; P0.0001), with consistent overall survival benefits across relevant subgroups.

Blinded independent central review also favored Ris-Rez across key secondary efficacy measures. Median progression-free survival was 7.2 months with Ris-Rez versus 3.0 months with topotecan (HR 0.33; 95% CI, 0.25–0.42). The objective response rate was 58.3% versus 12.6%, respectively, and the disease control rate was 90.4% versus 60.2%. Investigator-assessed outcomes were consistent with the central review findings.

Grade 3 or higher treatment-related adverse events occurred less frequently with Ris-Rez than with topotecan, at 60.9% versus 78.2%. The most common grade 3 or higher treatment-related adverse events were hematologic toxicities, including decreased neutrophil count, decreased white blood cell count, anemia, decreased lymphocyte count and decreased platelet count.

"Ris-Rez demonstrated a statistically significant and clinically meaningful overall survival benefit over topotecan in patients with SCLC that progressed after platinum-based therapy, with a favorable safety profile," said Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China.

"These results suggest the potential of Ris-Rez to define a new standard of care in relapsed SCLC."

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

Contact: Chris Martin, IASLC Media Relations, [email protected]

SOURCE International Association for the Study of Lung Cancer

Share this article